What is known about community pharmacy supply of naloxone? A scoping review

International Journal of Drug Policy

Volumn 32, Issue , 2016, Pages 24-33

  Nielsen, Suzanne ^a,b   Van Hout, Marie Claire ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^c South East Technological University   (Ireland)

Author keywords

Community pharmacy; Naloxone; Opioid; Overdose; Pharmacy; Supply systems

Indexed keywords

NALOXONE; OPIATE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

CINAHL; COCHRANE LIBRARY; DRUG FATALITY; DRUG OVERDOSE; EMBASE; HUMAN; INFORMATION RETRIEVAL; MEDLINE; PHARMACIST; PHARMACY; PRIORITY JOURNAL; PSYCINFO; SHORT SURVEY; OPIATE ADDICTION; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; SUPPLY AND DISTRIBUTION;

ANALGESICS, OPIOID; COMMUNITY PHARMACY SERVICES; DRUG OVERDOSE; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PHARMACISTS; PROFESSIONAL ROLE;

EID: 84959419050     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2016.02.006     Document Type: Short Survey

References (61)

1. Albert, S., Brason, F.W. 2nd, Sanford, C.K., Dasgupta, N., Graham, J., Lovette, B., Project Lazarus: Community-based overdose prevention in rural North Carolina. Pain Medicine 12:Suppl. 2 (2011), S77–S85.
2. Anderson, S., Allen, P., Peckham, S., Goodwin, N., Asking the right questions: Scoping studies in the commissioning of research on the organisation and delivery of health services. Health Research Policy and Systems, 6, 2008, 7.
3. Arksey, H., O'Malley, L., Scoping studies: Towards a methodological framework. International Journal of Social Research Methodology 8 (2005), 19–32.
4. Bailey, A.M., Wermeling, D.P., Naloxone for opioid overdose prevention: Pharmacists’ role in community-based practice settings. Annals of Pharmacotherapy 48 (2014), 601–606.
5. Behar, E., Santos, G.M., Wheeler, E., Rowe, C., Coffin, P.O., Brief overdose education is sufficient for naloxone distribution to opioid users. Drug and Alcohol Dependence 148 (2015), 209–212.
6. Beletsky, L., Rich, J.D., Walley, A.Y., Prevention of fatal opioid overdose. JAMA-Journal of the American Medical Association 308 (2012), 1863–1864.
7. Bennett, A.S., Bell, A., Tomedi, L., Hulsey, E.G., Kral, A.H., Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. Journal of Urban Health 88 (2011), 1020–1030.
8. Binswanger, I.A., Koester, S., Mueller, S., Gardner, E.M., Goddard, K., Glanz, J.M., Overdose education and naloxone prescribing for patients on chronic opioids: A qualitative study of health care providers. Journal of General Internal Medicine 29 (2014), S162–S163.
9. Burris, S., Norland, J., Edlin, B.R., Legal aspects of providing naloxone to heroin users in the United States. International Journal of Drug Policy 12 (2001), 237–248.
10. Butler, R., Sheridan, J., Innocent parties or devious drug users: The views of primary healthcare practitioners with respect to those who misuse prescription drugs. Harm Reduction Journal, 7, 2010, 21.
11. Clark, A.K., Wilder, C.M., Winstanley, E.L., A systematic review of community opioid overdose prevention and naloxone distribution programs. Journal of Addiction Medicine 8 (2014), 153–163.
12. Coffin, P.O., Sullivan, S.D., Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Annals of Internal Medicine 158 (2013), 1–9.
13. Daudt, H.M., van Mossel, C., Scott, S.J., Enhancing the scoping study methodology: A large, inter-professional team's experience with Arksey and O'Malley's framework. BMC Medical Research Methodology 13:48 (2013), 1–9, 10.1186/1471-2288-13-48.
14. Davidson, P.J., Lozada, R., Rosen, P.C., Macias, A., Gallardo, M., Pollini, R.A., Negotiating access: Social barriers to purchasing syringes at pharmacies in Tijuana, Mexico. The International Journal on Drug Policy 23 (2012), 286–294.
15. Davis, C.S., Carr, D., Southwell, J.K., Beletsky, L., Engaging law enforcement in overdose reversal initiatives: Authorization and liability for naloxone administration. American Journal of Public Health 105 (2015), 1530–1537.
16. Doe-Simkins, M., Quinn, E., Xuan, Z., Sorensen-Alawad, A., Hackman, H., Ozonoff, A., et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: A retrospective cohort study. BMC Public Health, 2014, 14.
17. Doe-Simkins, M., Walley, A.Y., Epstein, A., Moyer, P., Saved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose. American Journal of Public Health 99 (2009), 788–791.
18. Dong, K.A., Taylor, M., Wild, C.T., Villa-Roel, C., Rose, M., Salvalaggio, G., et al. Community-based naloxone: A Canadian pilot program. CJAM Canadian Journal of Addiction Medicine 3 (2012), 4–9.
19. Fenichel, R.R., Which drugs should be available over the counter? The criteria are clear and include safety, timeliness, and opportunity cost. BMJ: British Medical Journal 329 (2004), 182–183.
20. Firth, H., Todd, A., Bambra, C., Benefits and barriers to the public health pharmacy: A qualitative exploration of providers’ and commissioners’ perceptions of the Healthy Living Pharmacy framework. Perspectives in Public Health 135 (2015), 251–256.
21. Gaston, R.L., Best, D., Manning, V., Day, E., Can we prevent drug related deaths by training opioid users to recognise and manage overdoses?. Harm Reduction Journal, 6, 2009, 26.
22. George, S., Moreira, K., A guide for clinicians on take home naloxone prescribing. Addictive Disorders and Their Treatment 7 (2008), 163–167.
23. Gidman, W., Coomber, R., Contested space in the pharmacy: Public attitudes to pharmacy harm reduction services in the West of Scotland. Research in Social and Administrative Pharmacy 10 (2014), 576–587.
24. Giglio, R.E., Li, G., DiMaggio, C.J., Effectiveness of bystander naloxone administration and overdose education programs: A meta-analysis. Injury Epidemiology, 2015, 2.
25. Green, T.C., Dauria, E.F., Bratberg, J., Davis, C.S., Walley, A.Y., Case study. Orienting patients to greater opioid safety: Models of community pharmacy-based naloxone. Harm Reduction Journal, 2015, 1–9.
26. Hagemeier, N.E., Alamian, A., Murawski, M.M., Pack, R.P., Factors associated with provision of addiction treatment information by community pharmacists. Journal of Substance Abuse Treatment 52 (2015), 67–72.
27. Hammett, T.M., Phan, S., Gaggin, J., Case, P., Zaller, N., Lutnick, A., et al. Pharmacies as providers of expanded health services for people who inject drugs: A review of laws, policies, and barriers in six countries. BMC Health Services Research, 14, 2014, 261.
28. Hidalgo Landa, A., Szabo, I., Le Brun, L., Owen, I., Fletcher, G., Evidence based scoping review. The Electronic Journal Information Systems Evaluation 14 (2011), 46–52.
29. Hill, D., McAuley, A., A comparative study of stakeholder views on take-home naloxone services. Journal of Substance Use 17 (2012), 430–441.
30. Laird, A., Hunter, C., Glasgow city injecting equipment provision (IEP) pharmacy naloxone training pilot. International Journal of Pharmacy Practice S1 (2014), 2–27.
31. Leece, P.N., Hopkins, S., Marshall, C., Orkin, A., Gassanov, M.A., Shahin, R.M., Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario. Canadian Journal of Public Health. Revue Canadienne de Sante Publique 104 (2013), e200–e204.
32. Lenton, S.R., Dietze, P.M., Degenhardt, L., Darke, S., Butler, T.G., Naloxone for administration by peers in cases of heroin overdose. Medical Journal of Australia, 191, 2009, 469.
33. Levac, D., Colquhoun, H., O'Brien, K.K., Scoping studies: Advancing the methodology. Implementation Science: IS, 5, 2010, 69.
34. Liu, M., Mazur-Routsolias, J.C., Lu, J., Aks, S.E., Outpatient prescription naloxone in a county hospital emergency department: A pilot program. Clinical Toxicology 51:7 (2013), 718–719.
35. Mansoor, S.M., Krass, I., Costa, D.S., Aslani, P., Factors influencing the provision of adherence support by community pharmacists: A structural equation modeling approach. Research in Social and Administrative Pharmacy 11 (2015), 769–783.
36. Matheson, C., Bond, C.M., Tinelli, M., Community pharmacy harm reduction services for drug misusers: National service delivery and professional attitude development over a decade in Scotland. Journal of Public Health 29 (2007), 350–357.
37. Matheson, C., Thiruvothiyur, M., Robertson, H., Bond, C., Community pharmacy drug misuse services over two decades in Scotland: Implications for the future. International Journal of Drug Policy 27 (2016), 105–112.
38. Maxwell, J., The prescription drug epidemic in the United States: A perfect storm. Drug and Alcohol Review 30 (2011), 264–270.
39. Maxwell, S., Bigg, D., Stanczykiewicz, K., Carlberg-Racich, S., Prescribing naloxone to actively injecting heroin users: A program to reduce heroin overdose deaths. Journal of Addictive Diseases 25 (2006), 89–96.
40. Mayet, S., Manning, V., Williams, A., Loaring, J., Strang, J., Impact of training for healthcare professionals on how to manage an opioid overdose with naloxone: Effective, but dissemination is challenging. International Journal of Drug Policy 22 (2011), 9–15.
41. Pham, M.T., Rajić, A., Greig, J.D., Sargeant, J.M., Papadopoulos, A., McEwen, S.A., A scoping review of scoping reviews: Advancing the approach and enhancing the consistency. Research Synthesis Methods 5 (2014), 371–385.
42. Piper, T.M., Rudenstine, S., Stancliff, S., Sherman, S., Nandi, V., Clear, A., et al. Overdose prevention for injection drug users: Lessons learned from naloxone training and distribution programs in New York City. Harm Reduction Journal, 2007, 4.
43. Riner, E., Wermeling, D., Naloxone-based harm reduction: Implementation in the state of kentucky. Journal of the American Pharmacists Association, 54(2), 2014, e203.
44. Robinson, A., Wermeling, D.P., Intranasal naloxone administration for treatment of opioid overdose. American Journal of Health-System Pharmacy 71 (2014), 2129–2135.
45. Roxburgh, A., Burns, L., Accidental drug-induced deaths due to opioids in Australia, 2010. 2014, National Drug and Alcohol Research Centre, Sydney.
46. Rumrill, P.D., Fitzgerald, S.M., Merchant, W.R., Using scoping literature reviews as a means of understanding and interpreting existing literature. Work 35 (2010), 399–404.
47. Saramunee, K., Krska, J., Mackridge, A., Richards, J., Suttajit, S., Phillips-Howard, P., How to enhance public health service utilization in community pharmacy? General public and health providers’ perspectives. Research in Social and Administrative Pharmacy, 10, 2014.
48. Seal, K.H., Thawley, R., Gee, L., Bamberger, J., Kral, A.H., Ciccarone, D., et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: A pilot intervention study. Journal of Urban Health 82 (2005), 303–311.
49. Sheridan, J., Manning, V., Ridge, G., Mayet, S., Strang, J., Community pharmacies and the provision of opioid substitution services for drug misusers: Changes in activity and attitudes of community pharmacists across England 1995–2005. Addiction 102 (2007), 1824–1830.
50. Site Offers Free Online Naloxone Training, EMS World, 44, 2015, 14.
51. Straus, M.M., Ghitza, U.E., Tai, B., Preventing deaths from rising opioid overdose in the US – The promise of naloxone antidote in community-based naloxone take-home programs. Substance Abuse and Rehabilitation, 2013, 2013.
52. Therapeutic Goods Administration, Reasons for the scheduling delegate's interim decision and invitation for further comment for the ACMS, October 2015. Naloxone. 2015 http://www.tga.gov.au/interim-decisions-matters-referred-expert-advisory-committee-12-14. Retrieved 30th October 2015.
53. Thomson Reuters, Endnote X6. 2012, USW, New York.
54. Traynor, K., Rhode Island's opioid epidemic response features collaborative practice model. American Journal of Health-System Pharmacy 71 (2014), 1328–1332.
55. Vorobjov, S., Uusküla, A., Abel-Ollo, K., Talu, A., Jarlais, D.D., Should pharmacists have a role in harm reduction services for IDUs? A qualitative study in Tallinn, Estonia. Journal of Urban Health: Bulletin of the New York Academy of Medicine 86 (2009), 918–928.
56. Walley, A.Y., Xuan, Z., Hackman, H.H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. British Medical Journal, 346, 2013, f174.
57. Watson, T., Hughes, C., Pharmacists and harm reduction: A review of current practices and attitudes. Canadian Pharmacists Journal: CPJ, 145, 2012 124–127.e122.
58. Wenthur, C.J., Cross, B.S., Vernon, V.P., Shelly, J.L., Harth, B.N., Lienhoop, A.D., et al. Opinions and experiences of Indiana pharmacists and student pharmacists: The need for addiction and substance abuse education in the United States. Research in Social and Administrative Pharmacy 9 (2013), 90–100.
59. Wermeling, D.P., Opioid harm reduction strategies: Focus on expanded access to intranasal naloxone. Pharmacotherapy 30 (2010), 627–631.
60. Yates, J., Naloxone: The locked up lifesaver. The challenge of reducing drug related deaths in Birmingham, England. The International Naloxone Conference Bergen, Norway, 2015.
61. Zaller, N.D., Yokell, M.A., Green, T.C., Gaggin, J., Case, P., The feasibility of pharmacy-based naloxone distribution interventions: A qualitative study with injection drug users and pharmacy staff in Rhode Island. Substance Use and Misuse 48 (2013), 590–599.